Abstract
Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.
Original language | English (US) |
---|---|
Pages (from-to) | 1215-1216 |
Number of pages | 2 |
Journal | Mayo Clinic proceedings |
Volume | 80 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2005 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)